PFIZER
PFEPfizer Inc. (/ˈfaɪzər/ FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America.
Drugs in Pipeline
761
Phase 3 Programs
457
Upcoming Catalysts
35
Next Catalyst
Aug 4, 2026
4wMarket Overview
Stock performance and key metrics
43 upcoming, 4 past
PF-06821497 Phase 3 Est. Readout
Primary completion for PF-06821497 trial (NCT06551324) in Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Missed overall survival endpoint
Source42 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How PFE's past catalysts played out
FSME-IMMUN NEW 0.25 ml
Tick-borne Encephalitis
cefuroxime plus erythromycin
Pneumonia
PF-05280014
Metastatic Breast Cancer
Quillivant Oral Suspension XR
Attention Deficit Hyperactivity Disorder
Prevenar 13™
Infections, Meningococcal
Desvenlafaxine Succinate
Major Depressive Disorder
Enzalutamide
Breast Cancer
CP 690,550 5 mg
Psoriasis
Voriconazole
Neutropenia
indobufen
Atrial Fibrillation
Adalimumab
Rheumatoid Arthritis
PF-04965842 200 mg
Dermatitis
Methotrexate
Arthritis, Rheumatoid
desvenlafaxine 50 mg
Depressive Disorder, Major
Isovorin
Gastric Cancer
Nirmatrelvir
COVID-19
Doripenem
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Midazolam
Sedation
Artemether-lumefantrine
Malaria, Falciparum
Crizotinib
Non Small Cell Lung Cancer
Rapamune
Renal Allograft Recipients
Effexor XR
Depression
Fesoterodine PR 4 mg
Urinary Bladder, Neurogenic
cisplatin
Carcinoma, Non-Small-Cell Lung (NSCLC)
desipramine
Depression
procarbazine hydrochloride
Brain and Central Nervous System Tumors
Abrocitinib 100 mg
Atopic Dermatitis
desvenlafaxine succinate sustained release
Vasomotor Symptoms
Anidulafungin, VER002
Aspergillosis
treatment
Non Squamous Lung Cancer
Tofacitinib
Rheumatoid Arthritis
fluorouracil
Colorectal Cancer
Crisaborole 2%
Atopic Dermatitis
Duloxetine 60 mg/day
Depressive Disorder, Major
Etrasimod
Alopecia Areata
Elranatamab
Multiple Myeloma
Fenofibrate
Hyperlipidemia
Azithromycin SR
Acute Bronchitis
Disease-modifying antirheumatic drug
Arthritis, Rheumatoid
Ritlecitinib 100 mg
Vitiligo
20vPnC
Pneumococcal Disease
Genotonorm
Growth Disorders
Varenicline tartrate
Smoking Cessation
Irinotecan
Glioma
pegaptanib sodium
Macular Degeneration
tanezumab 5 mg
Arthritis
Tanezumab 2.5 mg
Osteoarthritis, Knee
rLP2086 vaccine
Meningitis, Meningococcal
Apixaban
Atrial Fibrillation
Azithromycin plus Chloroquine
Malaria
Talazoparib
Prostate Cancer
atorvastatin
Hypercholesterolemia, Familial
Fx-1006A
Familial Amyloid Polyneuropathy
Sulfadoxine-Pyrimethamine/Chloroquine
PLASMODIUM FALCIPARUM MALARIA
Mefloquine
Malaria, Falciparum
CP 690,550
Rheumatoid Arthritis
PN-152,243)/PN-196,444
Sarcoma
Physician's-Choice
Breast Neoplasms
Bazedoxifene Acetate
Osteoporosis
PF-04965842 100 mg
Dermatitis, Atopic
gemcitabine hydrochloride
Lung Cancer
Sigvotatug Vedotin
Non-Small Cell Lung Cancer
Epogen Amgen
Chronic Renal Failure
desvenlafaxine SR
Depression
Standard of Care FIX Replacement therapy
Hemophilia B
PVC (daily for 21 days, 7 days off)
Atrophic Vaginitis
Dexmedetomidine HCL Injection
Awake Fiberoptic Intubation
Bazedoxifene/Conjugated Estrogen
Vaginal Atrophy
desvenlafaxine succinate sustained release tablets
Major Depressive Disorder
Cyclosporine
Kidney Transplant
Amphotericin B
Mycoses
Pegvisomant
Acromegaly
Ceftaroline
Community-Acquired Bacterial Pneumonia
MenACWY-TT
Meningococcal ACWY Disease
Tamoxifen
Breast Neoplasms
PF-06741086
Hemophilia A
Clostridium difficile vaccine
Clostridium Difficile Associated Disease
DVS-SR 50 mg
Major Depressive Disorder
Varenicline
Smoking
RSVpreF Vaccine
Respiratory Syncytial Virus
Levofloxacin
Community-Acquired Infections
daunorubicin + cytarabine
Leukemia, Myeloid, Acute
Dimebon
Alzheimer's Disease
PF-06801591
Advanced Malignancies
fulvestrant
Uterine Neoplasms
Desvenlafaxine Sustained Release
Fibromyalgia
Bacillus Calmette-Guerin
Non-muscle Invasive Bladder Cancer
Pemetrexed
Carcinoma, Non-Small-Cell Lung
IBU BID
Pain
PF-07248144
Breast Cancer
PF-06838435/ fidanacogene elaparvovec
Hemophilia B
gemtuzumab ozogamicin
Leukemia
13vPnC + TIV
Pneumococcal Infections
Zyvox® / Linezolid
Bacterial Infections
CP-690,550 (tofacitinib)
Juvenile Idiopathic Arthritis
PF-02341066
Carcinoma, Non-Small-Cell Lung
Antibiotic
Pneumonia, Pneumococcal
Sunitinib + Capecitabine
Breast Neoplasms
Axitinib (AG-013736)
Hepatocellular Carcinoma
Osivelotor
Sickle Cell Disease
Imatinib
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
DIC075V (intravenous diclofenac sodium)
Pain, Postoperative
PhXA41
Glaucoma
Interferon Alfa
Carcinoma, Renal Cell
13-valent Pneumoccocal Conjugate Vaccine
Pneumococcal Conjugate Vaccine
PF-08634404
Carcinoma, Hepatocellular
Fragmin/ Dalteparin Sodium
Diabetic Foot Ulcer
Temsirolimus (CCI-779)
Advanced Renal Cell Carcinoma
Glasdegib
Acute Myeloid Leukemia
Rimegepant 25 MG
Migraine
chemotherapy
Leukemia
(PN-152,243)/ PN-196,444
Non-Hodgkin Lymphoma
fluoxetine
Major Depressive Disorder
MERREM I.V. 2g as a 3 hour infusion every 8 hours
Pneumonia
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Hemophilia A
Ertapenem
Bacterial Infections
Inclacumab
Sickle Cell Disease
Daratumumab
Multiple Myeloma
Dazukibart
Dermatomyositis
Docetaxel
Carcinoma, Non-Small-Cell Lung
Azithromycin microspheres 2.0 single dose
Community-Acquired Pneumonia
Mevrometostat
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Crisaborole Ointment
Atopic Dermatitis
Vanquix Auto-Injector (Diazepam Injection)
Seizures
Dexmedetomidine hydrochloride
Sedation
Rimegepant/BHV3000
Pediatric Migraine
PF-06438179
Rheumatoid Arthritis
Fentanyl
Anesthesia
Irinotecan + 5 FU + folinic acid
Colorectal Neoplasms
NSAID
Chronic Pain
Ritlecitinib lower dose
Severe Alopecia Areata
Epogen (Amgen)
Chronic Kidney Disease
PPSV23
Pneumococcal Disease
"Investigational"Auto-injector (sumatriptan succinate)
Migraine
VLA15
Lyme Borreliosis
Lenalidomide
Multiple Myeloma
Bococizumab (PF-04950615; RN316)
Hyperlipidemia
23-valent Pneumococcal Polysaccharide Vaccine
Pneumococcal Vaccines
BeneFIX
Hemophilia B
Background NSAID
Spondylitis, Ankylosing
VFEND® I.V., Oral
Candidiasis
DVS SR
Depressive Disorder, Major
PF-06821497
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Ribociclib
Breast Cancer
CP-945,598
Obesity
Ibuprofen 400 mg caplet
Patient Compliance
cabergoline
Restless Legs Syndrome
voriconazole (Vfend)
Candidiasis
Acetaminophen
Pain
Ceftriaxone sodium
Intra-abdominal Infections
Bazedoxifene Acetate (TSE-424)
Osteoporosis
Bococizumab 150mg
Hyperlipidemia
topotecan
Cervical Cancer
PF-08046054
Non-small Cell Carcinoma
Dupilumab
Dermatitis
CP-690, 550
Psoriasis
Rimegepant 75mg Orally Disintegrating Tablets (ODT)
Acute Migraine
CAZ-AVI
Complicated Intra-Abdominal Infection
Milnacipran
Depression
naproxen
Osteoarthritis
Ibuprofen 250 mg
Post-surgical Pain Following Extraction of Molar Teeth
Temsirolimus
Renal Cell Carcinoma
Etoposide + cisplatin
Small Cell Lung Carcinoma
20-valent pneumococcal conjugate vaccine (20vPnC)
Pneumococcal Disease
Unfractionated Heparin (UFH)
Deep Vein Thrombosis
tolterodine tartrate
Overactive Bladder
bazedoxifene BZA-20
Postmenopause
rimegepant 75 mg ODT
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Rapamune®
Kidney Disease
Pertuzumab
HER2 Positive Breast Cancer
Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Alopecia Areata
23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
HIV Infections
Anidulafungin
Neutropenia
adenosine
Coronary Artery Disease
Dexamethasone
Multiple Myeloma
Varenicline Tartarate
Smoking Cessation
Abrocitinib 200 mg
Dermatitis, Atopic
Placebp
Respiratory Syncytial Virus
Treatment with Genotropin in different dosages
Growth Disorder
prinomastat
Brain and Central Nervous System Tumors
MEK162
Metastatic Colorectal Cancer
Tofacitinib 5 mg BID
Psoriatic Arthritis
Abrocitinib
Atopic Dermatitis
5 fluorouracil
Metastatic Colorectal Cancer
LGX818
Solid Tumors Harboring a BRAF V600 Mutation
vemurafenib
Melanoma
Genotonorm (Somatropin)
Fetal Growth Retardation
Xyntha
Hemophilia A
Zavegepant (BHV-3500)
Acute Migraine
Desvenlafaxine succinate sustained release 50 mg
Major Depressive Disorder
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Respiratory Syncytial Virus (RSV)
SU011248
Gastrointestinal Stromal Tumors
Pantoprazole for approximately 9 weeks
Gastroesophageal Reflux
pantoprazole sodium enteric-coated spheroid
Gastroesophageal Reflux
Seasonal Inactivated Influenza Vaccine
Respiratory Syncytial Virus
Investigator's choice
Lymphoma
azithromycin (Zithromax)
Pharyngitis
IV Diclofenac
Postoperative Pain
Morphine
Sedation
oxaliplatin
Colorectal Neoplasms
Piperacillin/Tazobactam (Tazocin)
Hematologic Neoplasms
effervescent ibuprofen tablets
Pain
CP690,550
Ulcerative Colitis
Fesoterodine PR 8 mg
Urinary Bladder, Neurogenic
mycophenolate mofetil
Graft vs Host Disease
azithromycin sustained release
Pneumonia
FOLFIRI regimen
Colorectal Cancer
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
Osteoarthritis
leucovorin
Colorectal Carcinoma
azithromycin SR (Zithromax; compound: CP-62,993)
Maxillary Sinusitis
clarithromycin extended release (ER)
Pneumonia
Xiapex
Dupuytren's Contracture
MTZ
Complicated Intra-abdominal Infection
anastrozole
Breast Neoplasms
Standard of Care
Macular Edema Associated With Diabetes Mellitus
vaccine-13vPnC
Pneumococcal Infections
PF-04965842
Atopic Dermatitis
ATM-AVI
Complicated Intra-Abdominal Infections, cIAIs
Recombinant Coagulation Factor IX (BeneFIX)
Hemophilia B
Ibuprofen 250 mg / Acetaminophen 500 mg
Fever
Celecoxib
Schizophrenia
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
Encephalitis, Tick-Borne
Xalacom
Glaucoma, Open-Angle
Tanezumab 5 mg SC
Low Back Pain
Amlodipine
Hypertension
Topical IBU twice daily
Ankle Injuries
PLD
Ovarian Cancer
Lorlatinib
Carcinoma, Non-Small-Cell Lung
PMI-150 (intranasal ketamine)
Pain, Postoperative
Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Analgesia
Clostridium difficile
Clostridium Difficile Associated Disease
PD 0332334
Generalized Anxiety Disorder
Taxotere®
Early Breast Cancer
Ramipril and hydrochlorothiazide
Hypertension
PD-0332991
Neoplasms
UFT
Colon Cancer
PF-07275315 dose 1
Moderate to Severe Chronic Obstructive Pulmonary Disease
PF-08653944
Obesity
5-FU
Neoplasms
Leuprolide Open Label
Hormone Sensitive Prostate Cancer
MabThera®
Follicular Lymphoma
MenACWY-CRM
Meningococcal Vaccine
DA-9501
Sedation
paclitaxel
Breast Neoplasms
rLP2086
Healthy
Investigational Medical Product (IMP) administered in parent study
Osteoarthritis
VENLAFAXINE
Panic Disorders
tacrolimus
Kidney Transplantation
PF-05280586
Rheumatoid Arthritis
PG4
Pneumococcal Disease
Quadrivalent influenza modRNA vaccine
Influenza, Human
CE 0.45 mg/MPA 1.5mg
Endometrial Hyperplasia
voxelotor
Sickle Cell Disease
Standard Ibuprofen
Pain
23vPS
Vaccines, Pneumococcal Conjugate Vaccine
Solution Vehicle
Onychomycosis of Toenails
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg
Contraception
Megestrol acetate
Metastatic Breast Cancer
Lorazepam
Reflex Epilepsy, Photosensitive
RSVpreF MDV
Respiratory Syncytial Virus (RSV)
TBE vaccine 0.5 mL
Tick-Borne Encephalitis
Exubera (inhaled insulin)
Diabetes Mellitus, Type 2
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Gaucher Disease
ibuzatrelvir
COVID-19 Infection
Inotuzumab ozogamicin
ACUTE LYMPHOBLASTIC LEUKEMIA
7vPnC
Vaccines, Pneumococcal
Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
FLAG (fludarabine, cytarabine and G-CSF)
Acute Lymphoblastic Leukemia
MenABCWY
Meningococcal Vaccine
PF-06462700
Aplastic Anemia
Multivalent Group B streptococcus vaccine
Group B Streptococcus Infections
Infanrix hexa
Healthy
PF-06651600 Induction Dose
Alopecia Areata
C.difficile vaccine
Clostridioides Difficile Associated Disease
Celebrex
Osteoarthritis,Knee
Abemaciclib
Breast Cancer
propiverine
Urinary Bladder, Overactive
ATRA plus 6-MP and MTX
Leukemia, Myelocytic, Acute
Sirolimus (Rapamune®)
Renal Transplant
somatrogon
Growth Hormone Deficiency
ampicillin sodium/sulbactam sodium
Pneumonia, Bacterial
bifeprunox, olanzapine
Schizophrenia
(PN-152,243)/PN-196,444
Neoplasms
pantoprazole sodium enteric-coated spheroid suspension
Gastroesophageal Reflux
Chemotherapy Regimen 1
Advanced Non-Small Cell Lung Cancer
ALO-02
Chronic Pain
exemestane (Aromasin)
Breast Neoplasms
somatropin - GH naïve pediatric cohort
Prader-Willi Syndrome
Sirolimus (RAPAMUNE)
Graft vs Host Disease
Meningococcal group C polysaccharide conjugate vaccine
Neisseria Meningitidis
Donepezil (Aricept)
Alzheimer Disease
Moxifloxacin
Chronic Bronchitis
binodenoson
Coronary Artery Disease
Itraconazole
Antifungal Prophylaxis of Invasive Fungal Infections
bivalent rLP2086
Meningococcal Infection
Inhaled human insulin
Diabetes Mellitus, Type 1
Temozolomide
Glioblastoma
Hib
Pneumococcal Infections
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Pneumococcal Disease
Elotuzumab
Multiple Myeloma
FDC IBU/APAP 250 mg/500 mg
Pain
Matching vehicle control
Dermatitis, Atopic
Ritlecitinib 50 mg
Chronic Spontaneous Urticaria
Avelumab
Urothelial Cancer
DVS-233 SR (desvenlafaxine sustained release )
Major Depressive Disorder
Insulin Lispro
Diabetes Mellitus
Cyclosporine A
Renal Transplantation
13 valent pneumococcal conjugate vaccine with Polysorbate 80
Vaccines, Pneumococcal
Meropenem
Complicated Intra-abdominal Infections
MET097
Obesity
RSVpreF (Group 1)
RSV
Imipenem-cilastatin
Skin Infection
Diclofenac
Spondylitis, Ankylosing
Pediacel
Vaccines, Pneumococcal
Pemetrexed/Cisplatin
NSCLC (Non-small Cell Lung Cancer)
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
Menopause
Amoxicillin/clavulinic acid
Bronchitis, Chronic
desvenlafaxine succinate (DVS) SR
Vasomotor Symptoms
PF-06823859
Myositis
Ritlecitinib
Stable Nonsegmental Vitiligo
Nonacog alfa
Hemophilia B
Novel Ibuprofen
Pain
AG-013736
Carcinoma, Pancreatic Ductal
Epoetin Hospira Arm
Chronic Kidney Disease (CKD)
Azithromycin/Chloroquine
Malaria, Falciparum
Imipenem
Bacterial Pneumonia
marstacimab
Hemophilia A
Sunitinib
Neuroendocrine Tumors
Bosutinib
Polycystic Kidney, Autosomal Dominant
Inhaled Insulin
Asthma
Rimegepant
Acute Migraine
Bazedoxifene/Conjugate Estrogens (CE)
Endometrial Hyperplasia
7-valent Pneumococcal Conjugate Vaccine
Pneumococcal Infection
Modified Bolus 5-FU/LV with Irinotecan
Colorectal Neoplasms
varenicline (CP-526,555)
Smoking Cessation
Tigecycline
Gram-Positive Bacterial Infections
fesoterodine fumarate
Overactive Bladder
amoxicillin
Tonsillitis
SPM 907
Overactive Bladder Syndrome
Somatropin
Endocrine System Diseases
Parecoxib Sodium/Valdecoxib
Pain
Palbociclib
Breast Cancer
Pregabalin
Epilepsy, Partial
amoxicillin/clavulanate postassium (Augmentin ES-600)
Acute Otitis Media
DVS-233
Menopause
Tisotumab Vedotin
Cervical Cancer
13-valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
Sorafenib
Renal Cell Carcinoma
levonorgestrel/ethinyl estradiol
Menstruation Disturbances
Ritlecitinib higher dose
Severe Alopecia Areata
PF-07321332
COVID-19
AN2690 Topical Solution, 5%
Onychomycosis of Toenails
AN2728 Topical Ointment, 2%
Dermatitis, Atopic
Pentavac
Vaccines, Pneumococcal
Encorafenib
BRAF V600E-mutant Metastatic Colorectal Cancer
20-valent pneumococcal conjugate vaccine
Pneumococcal Disease
Talazoparib with enzalutamide
mCRPC
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)
Meningitis, Meningococcal
Letrozole
Breast Neoplasms
Genotropin
Idiopathic Short Stature
oxycodone HCl and naltrexone HCl extended-release capsules
Chronic Noncancer Pain
Zavegepant
Migraine
pantoprazole
Gastroesophageal Reflux
[S,S]-Reboxetine
Fibromyalgia
PF-06651600
Active Non-segmental Vitiligo
Taliglucerase alfa
Gaucher Disease
fluconazole
Tinea Capitis
PF-06410293
Rheumatoid Arthritis
linezolid
Febrile Neutropenia
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
Neisseria Meningitidis (Bacterial Meningitis)
Desvenlafaxine succinate sustained-release (DVS SR)
Depression
Epirubicin with Cyclophosphamide, followed by a Taxane
Adenocarcinoma
Ceftazidime-avibactam
Complicated Intra-abdominal Infection
talazoparib plus enzalutamide
Prostate Cancer
Ibuprofen/Caffeine
Pain
PF-06947386
Complicated Intra-abdominal Infection
tucatinib
HER2-positive Breast Cancer
CP-690,550
Crohn's Disease
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
Encephalitis, Tick-borne
Bococizumab (PF-04950615;RN316)
Hyperlipidemia
Azithromycin
Community Acquired Pneumonia (CAP)
ponsegromab
Non-small Cell Lung Cancer
Dexmedetomidine
Sedation
DVS-233 SR
Major Depressive Disorder
Dacomitinib (PF-00299804)
Non-Small Cell Lung Cancer
Genotropin (PN-180,307) Somatropin
Infant, Small for Gestational Age
exemestane
Breast Neoplasms
Erlotinib
Non-small Cell Lung Cancer
sumanirole
Parkinson Disease
UK-390,957
Ejaculation
torcetrapib/atorvastatin
Hyperlipidemia
RSVpreF
RSV Infection
disitamab vedotin
Urothelial Carcinoma
Fesoterodine
Overactive Bladder Syndrome
Nimenrix
Meningococcal Vaccine
7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Healthy Subjects
Meningococcal vaccine GSK134612
Infections, Meningococcal
13-valent pneumococcal conjugate vaccine (13vPnC)
Healthy Subjects
Moroctocog alfa (AF-CC)
Hemophilia A
lecozotan SR (SRA-333)
Alzheimer Disease
tanezumab 10 mg
Osteoarthritis
Desvenlafaxine Succinate Sustained-Release 10mg
Major Depressive Disorder
olmesartan alone or in combination with hydrochlorothiazide
Essential Hypertension
7 valent pneumococcal conjugate vaccine
Vaccines, Pneumococcal
Inhaled human insulin (EXUBERA™)
Diabetes Mellitus, Type 2
Tolterodine ER
Overactive Bladder
Fragmin
Diabetic Foot Ulcer
Tafamidis
Transthyretin (TTR) Amyloid Cardiomyopathy
Interferon-alfa
Carcinoma, Renal Cell
tanezumab
Arthritis
13vPnC
Vaccines, Pneumococcal Conjugate Vaccine
Rifabutin
Mycoses
endocrine-modulating drug therapy
Prostate Cancer
Ibuprofen Sodium
Pain
ceftazidim-avibactam (CAZ-AVI, experimental product)
Nosocomial Pneumonia (NP)
Gefitinib
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Carboplatin
Non-Small-Cell Lung Carcinoma
leflunomide
Prostate Cancer
Cyclosporin or tacrolimus
Graft Rejection
Edotecarin
Breast Neoplasms
Ceftaroline fosamil
Complicated Skin and Soft Tissue Infection
Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg
Oral Contraceptive
Enbrel (etanercept)
Ankylosing Spondylitis
Zmax
Otitis Media
Venlafaxine ER
Panic Disorder
vancomycin with aztreonam
Skin Diseases, Infectious
ARV-471
Advanced Breast Cancer
ARV-471 (PF-07850327)
Breast Cancer
valdecoxib
Pain
Havrix (HAV)
Meningococcal Vaccine
NWP09
Attention Deficit Hyperactivity Disorder
PF-07220060
Liposarcoma
Rimegepant (PF-07899801)
Acute Treatment of Migraine
13 valent Pneumococcal Conjugate Vaccine
Pneumococcal Infections
7vPnc pneumococcal conjugate vaccine
Vaccines, Pneumococcal
Bifeprunox
Schizophrenia
Epoetin Hospira
Chronic Renal Failure Requiring Hemodialysis
Sunitinib malate
Breast Neoplasms
Ethambutol hydrochloride
Mycobacterium Avium-intracellulare Infection
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Pain
ritonavir
COVID-19
ReFacto AF
Hemophilia A
binimetinib
MSS
ropinirole
Parkinson Disease
Sirolimus
Renal Transplantation
Desvenlafaxine Succinate Sustained-Release
Major Depressive Disorder
Gemcitabine
Pancreatic Neoplasms
Cetuximab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Ceftazidime - Avibactam ( CAZ-AVI)
Complicated Urinary Tract Infection
Vancomycin
Bacterial Infections
Dacarbazine
Metastatic or Unresectable Cutaneous Melanoma
Etanercept
Pulmonary Fibrosis
Avelumab (MSB0010718C)
Renal Cell Cancer
Steroids
Kidney Failure
rFIX
Hemophilia B
In open-label phase: treatment with tofacitinib
Arthritis Juvenile Idiopathic
Ibuprofen 600 mg ER
Pain
PF-08653945
Overweight
Tanezumab 20 mg IV
Low Back Pain
PF-04360365 10 mg/kg
Alzheimer's Disease
Prednisone
Prostatic Neoplasms
PF-06826647
Psoriasis
PF-07976016
Obesity
852A
Melanoma
PD 0200390
Nonrestorative Sleep
PF-03654764
Allergic Rhinitis
60 mg/kg azithromycin ER
Acute Otitis Media
CP-751, 871
Colorectal Neoplasm
PF-07850327, ARV-471, vepdegestrant
Locally Advanced or Metastatic ER+ HER2- Breast Cancer
CP-690-550
Arthritis, Rheumatoid
SU-011,248
Kidney Neoplasms
PF-610,355
Asthma
UK0369,003
Impotence
Multivalent Pneumococcal Vaccine - Formulation 1
Pneumococcal Disease
0.04 mg/kg CpG 7909
Carcinoma, Breast
PF-04217329 - Lowest Dose
Primary Open-Angle Glaucoma
Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral
Osteoarthritis of the Knee
Combination [RSVpreF+BNTb162b2]
Healthy Participants
PD-0299685
Hot Flashes
PF-04449913
Acute Myeloid Leukemia
axitinib
Carcinoma, Non-Small Cell Lung
CP-690,550 Vehicle
Dry Eye Syndromes
PF-06291874
Diabetes Mellitus, Type II
Mylotarg (gemtuzumab ozogamicin) Injection
Acute Myelogenous Leukemia
AN2690, 2.5%
Distal, Subungual Onychomycosis
tofacitinib ointment 20 mg/g
Psoriasis Vulgaris
AN2728 ointment, 2%
Psoriasis
PF-06882961
Diabetes
PF-00489791
Diabetic Nephropathies
PD 0299685 at 15mg BID
Interstitial Cystitis
UK-453, 061
HIV-1
PF-05089771 150 mg
Diabetic Neuropathy, Painful
Celecoxib, COX-2 inhibitor; oral
Dental Pain
ARRY-502, CRTh2 antagonist; oral
Asthma
Levonorgestrel
Ovulation
Formulation A
Respiratory Tract Infections
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Shingles
CPG 7909 Injection
Carcinoma, Melanoma
PF-04383119
Cystitis, Interstitial
PF-06882961 (Cohorts 1 and 2)
Obesity
Multivalent
Pneumococcal Infections
Bazedoxifene
Postmenopausal Osteoporosis
Filibuvir
Hepatitis
PF-05221304
Nonalcoholic Fatty Liver Disease
ARRY-520, KSP(Eg5) inhibitor; intravenous
Multiple Myeloma
AN2728
Psoriasis
FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
Colorectal Neoplasms
vabicaserin
Schizophrenia
TMI-005
Rheumatoid Arthritis
Crisaborole ointment 2% BID
Dermatitis, Atopic
ibuprofen
Pain
Doxycycline
Non Small Cell Lung Cancer (NSCLC)
ARRY-438162, MEK inhibitor; oral
Rheumatoid Arthritis
ACC-001
Alzheimer's Disease
FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
Unresectable or Metastatic Colorectal Cancer
MET097 Injection
Obesity in Diabetes
IMA-638
Asthma
SKI-606 (Bosutinib)
Chronic Myelogenous Leukemia
Influenza ModRNA Vaccine
Influenza, Human
SCA-136 (200 mg)
Schizophrenia
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
Group B Streptococcal Infections
Tofacitinib 2 mg
Ankylosing Spondylitis
meningococcal B rLP2086 vaccine.
Meningitis, Meningococcal
PF-06463922
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Tofacitinib ointment 20mg/g
Dermatitis, Atopic
PF-04217329
Glaucoma, Open-Angle
Ezetimibe
Hypercholesterolemia
vepdegestrant
Breast Cancer
PF-04236921
Crohn's Disease
Tamsulosin
Prostatic Hyperplasia
PF-06865571
Nonalcoholic Steatohepatitis
Chemotherapy Regimen 2
Carcinoma
Vaccine Candidate #1
Healthy Adults
IMA-638 is a biologic
Asthma
CPG 7909
Carcinoma, Non-Small Cell Lung
Anrukinzumab
Colitis, Ulcerative
AG013736
Thyroid Neoplasms
azithromycin immediate release (Zithromax)
Pharmacokinetics
PH-797804
Pulmonary Disease, Chronic Obstructive
Tolterodine & Pregabalin
Overactive Bladder
Herceptin®
Carcinoma, Metastatic Breast
PF-00592379
Impotence
Peg-Intron
Hepatitis C
PF-07868489
Pulmonary Arterial Hypertension
PF-06700841
Psoriatic Arthritis
Filanesib, KSP (Eg5) inhibitor; intravenous
Advanced Multiple Myeloma
Enfortumab Vedotin
Urothelial Cancer
exemestane (Aromasin®)
Breast Neoplasms
SS-RBX
Urinary Incontinence, Stress
sulopenem and PF-03709270
Pneumonia, Bacterial
bapineuzumab
Alzheimer Disease
RV521
Respiratory Syncytial Virus Infections
Allegra
Allergic Rhinitis
Irinotecan plus capecitabine
Carcinoma, Hepatocellular
Elranatamab (PF-06863135)
Multiple Myeloma
PF-00734200 30 mg QD
Diabetes Mellitus, Type 2
Anti-Beta Interferon (PF-06823859)
Dermatomyositis
Tasocitinib plus Methotrexate
Rheumatoid Arthritis
AG-013726
Colorectal Neoplasms
PF-07220060 + PF-07104091 combination dose escalation
Breast Cancer
EXC 001
Scar Prevention
SAM-531
Alzheimer Disease
Celecoxib + Exemestane
Breast Neoplasms
WNT974
Metastatic Colorectal Cancer
PF-04634817
Diabetic Nephropathy
EXC 001 (currently called PF-06473871)
Reduction in Severity of Skin Scarring
CP-778,875
Dyslipidemia
ACC-001 + QS-21
Alzheimer Disease
CP-533, 536
Tibial Fractures
SBI-087
Active Rheumatoid Arthritis
ceftazidime/NXL104 + metronidazole
Complicated Intra-abdominal Infections
PF-04494700 - Low Dose Arm
Alzheimer Disease
cytarabine.
Acute Myeloid Leukemia
CCI-779
Multiple Sclerosis, Relapsing-Remitting
rhBMP-2/CPM
Fractures
PELITREXOL/AG-2037
Colorectal Neoplasms
CE-224,535
Arthritis, Rheumatoid
BNT162b2 (Omi XBB.1.5)/RIV
Influenza, Human
sunitinib malate dose escalation
Gastrointestinal Stromal Tumors
MultiStem low dose
Colitis, Ulcerative
rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Osteoporosis
Carfilzomib, proteasome inhibitor; intravenous
Advanced Multiple Myeloma
PF-06835375
Primary Immune Thrombocytopenia
Torisel
Adenocarcinoma
SPK-9001
Hemophilia B
CP-866,087
Alcoholism
PF-06835919
Non-alcoholic Steatohepatitis
ARRY-334543, EGFR/ErbB2 inhibitor; oral
Advanced Cancer
Tygacil
Bacterial Infections
ARRY-371797, p38 inhibitor; oral
LMNA-Related Dilated Cardiomyopathy
C. difficile vaccine (previously studied formulation).
Clostridoides Difficile Associated Disease
CP-751,871
Prostatic Neoplasms
CPG10101
Hepatitis, Chronic Active
PF-06372865
Chronic Low Back Pain
lecozotan SR
Alzheimer Disease
RSV Vaccine
Respiratory Tract Infection
Kaletra
HIV Infections
BYL719
Colorectal Cancer
MYO-029
Becker Muscular Dystrophy
(Part C) MET097
Obesity and Overweight
dalteparin
Venous Thromboembolism
HSP-130
Non-metastatic Breast Cancer
SRA-333
Alzheimer's Disease
Dacomitinib
Non-small Cell Lung Cancer
PF-00232798
HIV
SB-525 (PF-07055480)
Hemophilia A
PF-07817883
SARS-CoV-2 Infection
CI-1040
Colorectal Neoplasms
PF-04171327 10 mg
Rheumatoid Arthritis
PF-07104091 monotherapy dose escalation
Small Cell Lung Cancer
PF-04950615 (RN316)
Hypercholesterolemia
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Parkinson's Disease
PF-04360365 0.1 mg/kg
Alzheimer's Disease
Sunitinib malate (SU011248)
Gastrointestinal Stromal Tumors
PF-3512676 + Erlotinib
Carcinoma, Non-Small-Cell Lung
Low Dose PF-07328948
Heart Failure
SU011248 (sunitinib)
Carcinoma, Renal Cell Metastasis
PF-04383119 (RN624)
Low Back Pain
PF-04937319 10 mg
Diabetes Mellitus, Type 2
Rapamune® (Sirolimus)
Kidney Transplantation
MET233 and MET097
Obesity and Obesity-related Medical Conditions
NMDA Antagonist, CP-101,606 (traxoprodil)
Depressive Disorder, Major
SD-6010
Osteoarthritis
CP-690,550 Ointment 1
Psoriasis
AN2690
Onychomycosis
Statin
Hypercholesterolemia
PF-00299804
Carcinoma, Non Small Cell Lung
PF-08049820
Atopic Dermatitis
Letrozole / Temsirolimus (CCI-779)
Breast Neoplasms
PF-04383119 (tanezumab)
Osteoarthritis, Knee
Vaccine
Meningococcal Vaccine
Sunitinib (SU011248)
Liver Neoplasms
Combination 1
Carcinoma, Renal Cell
Samuraciclib
Breast Cancer
tacedinaline
Pancreatic Cancer
150 mg PF-04991532
Diabetes, Type 2
AN2728 Ointment Vehicle
Psoriasis
inotuzumab ozogamicin (CMC-544)
Lymphoma, B-Cell
Ceftazidime -avibactam
Complicated Urinary Tract Infections
CE-326,597 100 mg QD
Weight Management
CI-1033
Breast Neoplasms
PF-06823859 low
Dermatomyositis
PF-04494700 (TTP488)
Diabetic Nephropathy
Repevax
Meningococcal Vaccine
PF-03654746
Excessive Daytime Sleepiness
UK-453,061
HIV-1
PF-00217830
Schizophrenia
EKB-569
Colorectal Neoplasms
pregabalin/PF-00489791
Postherpetic Neuralgia
CI 1033
Lung Neoplasms
CP-690,550 + methotrexate
Rheumatoid Arthritis
PF-04136309
Osteoarthritis, Knee
Open
Chronic Kidney Disease
QS-21
Alzheimer Disease
ACC-001 3 μg/ QS-21 50 μg
Alzheimer's Disease
PF-00446687
Erectile Dysfunction
Gefitinib + Sunitinib
Carcinoma, Renal Cell
ERB-041
Endometriosis
PF-06838435 (formerly SPK-9001)
Hemophilia B
AG-013736 (Axitinib)
Acute Myeloid Leukemia (AML)
Zithromax™ (azithromycin) 500mg tablets
Sinusitis
LEE011
Locally Advanced or Metastatic NRAS Mutant Melanoma
Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
Kidney Neoplasms
RN624
Neuralgia, Postherpetic
PF-04937319 - 3mg
Type 2 Diabetes Mellitus
PF-04494700
Alzheimer's Disease
PD-217,014
Irritable Bowel Syndrome
AN2690, 5%
Distal, Subungual Onychomycosis
CP-690,550 Eye drops
Dry Eye Syndromes
Axitinib [AG-013736]
Melanoma
Tofimilast
Asthma
BGJ398
Melanoma
PF-00734200 10 mg QD
Diabetes Mellitus, Type 2
Tick-borne Encephalitis Vaccine
Tick-borne Encephalitis
PF-02545920
Huntington's Disease
Sumatriptan
Migraine
25 mg PF-04991532
Diabetes Mellitus, Type 2
PF-06650833
Acne Inversa
Ibuprofen/acetaminophen
Pain
CP-526,555 (varenicline)
Smoking Cessation
PF-05089771
Postoperative Dental Pain
MAC-321
Colorectal Neoplasms
MET233
Obesity and Overweight
PF-00610355
Pulmonary Disease, Chronic Obstructive
mPnC candidate
Healthy Participants
Dexmedetomidine, midazolam; fentanyl
Intubated and Mechanically Ventilated Pediatric Subjects
CP- 690 550
Ulcerative Colitis
Capecitabine
Breast Cancer
PF-04191834
Asthma
PF-04171327
Rheumatoid Arthritis
mIRV
Influenza, Human
Risperidone
Schizophrenia
ILV-094
Rheumatoid Arthritis
Leuprolide
Prostate Cancer
Anti-NGF AB
Neoplasms
Methotrexate plus ERB-041 for 12 weeks
Rheumatoid Arthritis
Vupanorsen
Dyslipidemias
active comparator
Pulmonary Disease, Chronic Obstructive
Atomoxetine
Attention Deficit Disorder With Hyperactivity
cyclophosphamide
Peripheral T-cell Lymphoma
RN624 (PF-04383119)
Osteoarthritis
Elranatamab + Nirogacestat
Multiple Myeloma
AN2898 ointment, 1%
Dermatitis, Atopic
PBO
Hypercholesterolemia
AN2690 Solution, 5.0%
Onychomycosis
Tisotumab vedotin (HuMax-TF-ADC)
Ovary Cancer
Naproxen + PH-797804
Osteoarthritis
ALO-01
Healthy
Sitexsentin sodium
Diastolic Heart Failure
Capravirine
Human Immunodeficiency Virus
Bivalent rLP2086 Vaccine
MENINGOCOCCAL INFECTION
Meningococcal C
Meningitis, Meningococcal
PD 0348292
Venous Thrombosis
PF-07275315
Asthma
PF-06835919 Low Dose
Non-alcoholic Fatty Liver Disease
PF-00868554
Hepatitis C
Staphylococcus aureus 4-antigen vaccine
Staphylococcal Infections
Sertraline and Elzasonan Combination
Depressive Disorder, Major
Part A: ATM-AVI Single Dose, Cohorts 1-4
Gram-negative Bacterial Infection
MRE0094
Foot Ulcer, Diabetic
BAT
Gram-negative Bacterial Infections
Investigational drug
Carcinoma, Non-Small-Cell Lung
SU011248 capsule
Carcinoma, Renal Cell
PF-07220060 CDK4 inhibitor
Advanced or Metastatic Breast Cancer
Bortezomib
Multiple Myeloma
Pediatric HAV vaccine
Meningococcal B Disease
AN2728 Topical Ointment, 2% QD
Dermatitis, Atopic
PF-05221304 Monotherapy
Non-Alcoholic Fatty Liver Disease (NAFLD)
Crisaborole ointment 2%
Atopic Dermatitis
PF-07264660
Atopic Dermatitis
PF-3512676
Lymphoma, T-Cell, Cutaneous
UK-369,003
Prostatic Hyperplasia
PF-06700841 15 mg
Systemic Lupus Erythematosus
Tanezumab 10 mg IV
Neoplasm Metastasis
Ponezumab
Cerebral Amyloid Angiopathy
PF-07038124 ointment
Atopic Dermatitis
CP-547,632
Ovarian Neoplasms
Esreboxetine
Fibromyalgia
maplirpacept (PF-07901801)
Diffuse Large B-Cell Lymphoma
PF-04236921 SC injection
Crohn's Disease
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Depression
15-valent pneumococcal conjugate vaccine (PCV15)
Pneumococcal Disease
PF-04447943
Alzheimer's Disease
ACC-001(3µg) + QS21
Alzheimer Disease
PD 0332991
Breast Cancer
SU014813
Breast Neoplasms
Tdap
Pneumococcal Infections
rLP2086 + MCV4 + Tdap
Vaccines
(CP-6890,550) Tofacitinib
Plaque Psoriasis
PF-06473871
Reduction of Hypertrophic Skin Scarring
meningococcal B rLP2086 vaccine candidate
Meningitis, Meningococcal
ARRY-371797, p38 inhibitor, oral
LMNA-Related Dilated Cardiomyopathy
PF-04457845
Osteoarthritis, Knee
Recombinant Human Interleukin-11 (rhIL-11)
Crohn Disease
sitaxsentan (Thelin)
Cardiac Surgery Subjects
Bicalutamide
Prostate Cancer
Sunitinib Malate Continuous Daily Dosing
Carcinoma, Renal Cell
Combination Agent 1
Advanced/Metastatic Non-Small Cell Lung Cancer
PF-07038124 ointment 0.01%
Atopic Dermatitis
NXL104/ceftazidime
Complicated Urinary Tract Infection
rLP2086 and Gardasil
Vaccines
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FSME-IMMUN NEW 0.25 ml | Phase 3 | Tick-borne Encephalitis | - | - |
cefuroxime plus erythromycin | Phase 3 | Pneumonia | - | - |
PF-05280014 | Phase 3 | Metastatic Breast Cancer | - | - |
Quillivant Oral Suspension XR | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Prevenar 13™ | Phase 3 | Infections, Meningococcal | - | - |
Desvenlafaxine Succinate | Phase 3 | Major Depressive Disorder | - | - |
Enzalutamide | Phase 3 | Breast Cancer | - | - |
CP 690,550 5 mg | Phase 3 | Psoriasis | - | - |
Voriconazole | Phase 3 | Neutropenia | - | - |
indobufen | Phase 3 | Atrial Fibrillation | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
PF-04965842 200 mg | Phase 3 | Dermatitis | - | - |
Methotrexate | Phase 3 | Arthritis, Rheumatoid | - | - |
desvenlafaxine 50 mg | Phase 3 | Depressive Disorder, Major | - | - |
Isovorin | Phase 3 | Gastric Cancer | - | - |
Nirmatrelvir | Phase 3 | COVID-19 | - | - |
Doripenem | Phase 3 | Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | - | - |
Midazolam | Phase 3 | Sedation | - | - |
Artemether-lumefantrine | Phase 3 | Malaria, Falciparum | - | - |
Crizotinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
Rapamune | Phase 3 | Renal Allograft Recipients | - | - |
Effexor XR | Phase 3 | Depression | - | - |
Fesoterodine PR 4 mg | Phase 3 | Urinary Bladder, Neurogenic | - | - |
cisplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung (NSCLC) | - | - |
desipramine | Phase 3 | Depression | - | - |
procarbazine hydrochloride | Phase 3 | Brain and Central Nervous System Tumors | - | - |
Abrocitinib 100 mg | Phase 3 | Atopic Dermatitis | - | - |
desvenlafaxine succinate sustained release | Phase 3 | Vasomotor Symptoms | - | - |
Anidulafungin, VER002 | Phase 3 | Aspergillosis | - | - |
treatment | Phase 3 | Non Squamous Lung Cancer | - | - |
Tofacitinib | Phase 3 | Rheumatoid Arthritis | - | - |
fluorouracil | Phase 3 | Colorectal Cancer | - | - |
Crisaborole 2% | Phase 3 | Atopic Dermatitis | - | - |
Duloxetine 60 mg/day | Phase 3 | Depressive Disorder, Major | - | - |
Etrasimod | Phase 3 | Alopecia Areata | - | - |
Elranatamab | Phase 3 | Multiple Myeloma | - | - |
Fenofibrate | Phase 3 | Hyperlipidemia | - | - |
Azithromycin SR | Phase 3 | Acute Bronchitis | - | - |
Disease-modifying antirheumatic drug | Phase 3 | Arthritis, Rheumatoid | - | - |
Ritlecitinib 100 mg | Phase 3 | Vitiligo | - | - |
20vPnC | Phase 3 | Pneumococcal Disease | - | - |
Genotonorm | Phase 3 | Growth Disorders | - | - |
Varenicline tartrate | Phase 3 | Smoking Cessation | - | - |
Irinotecan | Phase 3 | Glioma | - | - |
pegaptanib sodium | Phase 3 | Macular Degeneration | - | - |
tanezumab 5 mg | Phase 3 | Arthritis | - | - |
Tanezumab 2.5 mg | Phase 3 | Osteoarthritis, Knee | - | - |
rLP2086 vaccine | Phase 3 | Meningitis, Meningococcal | - | - |
Apixaban | Phase 3 | Atrial Fibrillation | - | - |
Azithromycin plus Chloroquine | Phase 3 | Malaria | - | - |
Talazoparib | Phase 3 | Prostate Cancer | - | - |
atorvastatin | Phase 3 | Hypercholesterolemia, Familial | - | - |
Fx-1006A | Phase 3 | Familial Amyloid Polyneuropathy | - | - |
Sulfadoxine-Pyrimethamine/Chloroquine | Phase 3 | PLASMODIUM FALCIPARUM MALARIA | - | - |
Mefloquine | Phase 3 | Malaria, Falciparum | - | - |
CP 690,550 | Phase 3 | Rheumatoid Arthritis | - | - |
PN-152,243)/PN-196,444 | Phase 3 | Sarcoma | - | - |
Physician's-Choice | Phase 3 | Breast Neoplasms | - | - |
Bazedoxifene Acetate | Phase 3 | Osteoporosis | - | - |
PF-04965842 100 mg | Phase 3 | Dermatitis, Atopic | - | - |
gemcitabine hydrochloride | Phase 3 | Lung Cancer | - | - |
Sigvotatug Vedotin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Epogen Amgen | Phase 3 | Chronic Renal Failure | - | - |
desvenlafaxine SR | Phase 3 | Depression | - | - |
Standard of Care FIX Replacement therapy | Phase 3 | Hemophilia B | - | - |
PVC (daily for 21 days, 7 days off) | Phase 3 | Atrophic Vaginitis | - | - |
Dexmedetomidine HCL Injection | Phase 3 | Awake Fiberoptic Intubation | - | - |
Bazedoxifene/Conjugated Estrogen | Phase 3 | Vaginal Atrophy | - | - |
desvenlafaxine succinate sustained release tablets | Phase 3 | Major Depressive Disorder | - | - |
Cyclosporine | Phase 3 | Kidney Transplant | - | - |
Amphotericin B | Phase 3 | Mycoses | - | - |
Pegvisomant | Phase 3 | Acromegaly | - | - |
Ceftaroline | Phase 3 | Community-Acquired Bacterial Pneumonia | - | - |
MenACWY-TT | Phase 3 | Meningococcal ACWY Disease | - | - |
Tamoxifen | Phase 3 | Breast Neoplasms | - | - |
PF-06741086 | Phase 3 | Hemophilia A | - | - |
Clostridium difficile vaccine | Phase 3 | Clostridium Difficile Associated Disease | - | - |
DVS-SR 50 mg | Phase 3 | Major Depressive Disorder | - | - |
Varenicline | Phase 3 | Smoking | - | - |
RSVpreF Vaccine | Phase 3 | Respiratory Syncytial Virus | - | - |
Levofloxacin | Phase 3 | Community-Acquired Infections | - | - |
daunorubicin + cytarabine | Phase 3 | Leukemia, Myeloid, Acute | - | - |
Dimebon | Phase 3 | Alzheimer's Disease | - | - |
PF-06801591 | Phase 3 | Advanced Malignancies | - | - |
fulvestrant | Phase 3 | Uterine Neoplasms | - | - |
Desvenlafaxine Sustained Release | Phase 3 | Fibromyalgia | - | - |
Bacillus Calmette-Guerin | Phase 3 | Non-muscle Invasive Bladder Cancer | - | - |
Pemetrexed | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
IBU BID | Phase 3 | Pain | - | - |
PF-07248144 | Phase 3 | Breast Cancer | - | - |
PF-06838435/ fidanacogene elaparvovec | Phase 3 | Hemophilia B | - | - |
gemtuzumab ozogamicin | Phase 3 | Leukemia | - | - |
13vPnC + TIV | Phase 3 | Pneumococcal Infections | - | - |
Zyvox® / Linezolid | Phase 3 | Bacterial Infections | - | - |
CP-690,550 (tofacitinib) | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
PF-02341066 | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Antibiotic | Phase 3 | Pneumonia, Pneumococcal | - | - |
Sunitinib + Capecitabine | Phase 3 | Breast Neoplasms | - | - |
Axitinib (AG-013736) | Phase 3 | Hepatocellular Carcinoma | - | - |
Osivelotor | Phase 3 | Sickle Cell Disease | - | - |
Imatinib | Phase 3 | Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | - | - |
DIC075V (intravenous diclofenac sodium) | Phase 3 | Pain, Postoperative | - | - |
PhXA41 | Phase 3 | Glaucoma | - | - |
Interferon Alfa | Phase 3 | Carcinoma, Renal Cell | - | - |
13-valent Pneumoccocal Conjugate Vaccine | Phase 3 | Pneumococcal Conjugate Vaccine | - | - |
PF-08634404 | Phase 3 | Carcinoma, Hepatocellular | - | - |
Fragmin/ Dalteparin Sodium | Phase 3 | Diabetic Foot Ulcer | - | - |
Temsirolimus (CCI-779) | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Glasdegib | Phase 3 | Acute Myeloid Leukemia | - | - |
Rimegepant 25 MG | Phase 3 | Migraine | - | - |
chemotherapy | Phase 3 | Leukemia | - | - |
(PN-152,243)/ PN-196,444 | Phase 3 | Non-Hodgkin Lymphoma | - | - |
fluoxetine | Phase 3 | Major Depressive Disorder | - | - |
MERREM I.V. 2g as a 3 hour infusion every 8 hours | Phase 3 | Pneumonia | - | - |
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy | Phase 3 | Hemophilia A | - | - |
Ertapenem | Phase 3 | Bacterial Infections | - | - |
Inclacumab | Phase 3 | Sickle Cell Disease | - | - |
Daratumumab | Phase 3 | Multiple Myeloma | - | - |
Dazukibart | Phase 3 | Dermatomyositis | - | - |
Docetaxel | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Azithromycin microspheres 2.0 single dose | Phase 3 | Community-Acquired Pneumonia | - | - |
Mevrometostat | Phase 3 | Metastatic Castration Sensitive Prostate Cancer (mCSPC) | - | - |
Crisaborole Ointment | Phase 3 | Atopic Dermatitis | - | - |
Vanquix Auto-Injector (Diazepam Injection) | Phase 3 | Seizures | - | - |
Dexmedetomidine hydrochloride | Phase 3 | Sedation | - | - |
Rimegepant/BHV3000 | Phase 3 | Pediatric Migraine | - | - |
PF-06438179 | Phase 3 | Rheumatoid Arthritis | - | - |
Fentanyl | Phase 3 | Anesthesia | - | - |
Irinotecan + 5 FU + folinic acid | Phase 3 | Colorectal Neoplasms | - | - |
NSAID | Phase 3 | Chronic Pain | - | - |
Ritlecitinib lower dose | Phase 3 | Severe Alopecia Areata | - | - |
Epogen (Amgen) | Phase 3 | Chronic Kidney Disease | - | - |
PPSV23 | Phase 3 | Pneumococcal Disease | - | - |
"Investigational"Auto-injector (sumatriptan succinate) | Phase 3 | Migraine | - | - |
VLA15 | Phase 3 | Lyme Borreliosis | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Bococizumab (PF-04950615; RN316) | Phase 3 | Hyperlipidemia | - | - |
23-valent Pneumococcal Polysaccharide Vaccine | Phase 3 | Pneumococcal Vaccines | - | - |
BeneFIX | Phase 3 | Hemophilia B | - | - |
Background NSAID | Phase 3 | Spondylitis, Ankylosing | - | - |
VFEND® I.V., Oral | Phase 3 | Candidiasis | - | - |
DVS SR | Phase 3 | Depressive Disorder, Major | - | - |
PF-06821497 | Phase 3 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
CP-945,598 | Phase 3 | Obesity | - | - |
Ibuprofen 400 mg caplet | Phase 3 | Patient Compliance | - | - |
cabergoline | Phase 3 | Restless Legs Syndrome | - | - |
voriconazole (Vfend) | Phase 3 | Candidiasis | - | - |
Acetaminophen | Phase 3 | Pain | - | - |
Ceftriaxone sodium | Phase 3 | Intra-abdominal Infections | - | - |
Bazedoxifene Acetate (TSE-424) | Phase 3 | Osteoporosis | - | - |
Bococizumab 150mg | Phase 3 | Hyperlipidemia | - | - |
topotecan | Phase 3 | Cervical Cancer | - | - |
PF-08046054 | Phase 3 | Non-small Cell Carcinoma | - | - |
Dupilumab | Phase 3 | Dermatitis | - | - |
CP-690, 550 | Phase 3 | Psoriasis | - | - |
Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Phase 3 | Acute Migraine | - | - |
CAZ-AVI | Phase 3 | Complicated Intra-Abdominal Infection | - | - |
Milnacipran | Phase 3 | Depression | - | - |
naproxen | Phase 3 | Osteoarthritis | - | - |
Ibuprofen 250 mg | Phase 3 | Post-surgical Pain Following Extraction of Molar Teeth | - | - |
Temsirolimus | Phase 3 | Renal Cell Carcinoma | - | - |
Etoposide + cisplatin | Phase 3 | Small Cell Lung Carcinoma | - | - |
20-valent pneumococcal conjugate vaccine (20vPnC) | Phase 3 | Pneumococcal Disease | - | - |
Unfractionated Heparin (UFH) | Phase 3 | Deep Vein Thrombosis | - | - |
tolterodine tartrate | Phase 3 | Overactive Bladder | - | - |
bazedoxifene BZA-20 | Phase 3 | Postmenopause | - | - |
rimegepant 75 mg ODT | Phase 3 | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | - | - |
Rapamune® | Phase 3 | Kidney Disease | - | - |
Pertuzumab | Phase 3 | HER2 Positive Breast Cancer | - | - |
Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine | Phase 3 | Alopecia Areata | - | - |
23-valent Pneumococcal Polysaccharide Vaccine (23vPS) | Phase 3 | HIV Infections | - | - |
Anidulafungin | Phase 3 | Neutropenia | - | - |
adenosine | Phase 3 | Coronary Artery Disease | - | - |
Dexamethasone | Phase 3 | Multiple Myeloma | - | - |
Varenicline Tartarate | Phase 3 | Smoking Cessation | - | - |
Abrocitinib 200 mg | Phase 3 | Dermatitis, Atopic | - | - |
Placebp | Phase 3 | Respiratory Syncytial Virus | - | - |
Treatment with Genotropin in different dosages | Phase 3 | Growth Disorder | - | - |
prinomastat | Phase 3 | Brain and Central Nervous System Tumors | - | - |
MEK162 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Tofacitinib 5 mg BID | Phase 3 | Psoriatic Arthritis | - | - |
Abrocitinib | Phase 3 | Atopic Dermatitis | - | - |
5 fluorouracil | Phase 3 | Metastatic Colorectal Cancer | - | - |
LGX818 | Phase 3 | Solid Tumors Harboring a BRAF V600 Mutation | - | - |
vemurafenib | Phase 3 | Melanoma | - | - |
Genotonorm (Somatropin) | Phase 3 | Fetal Growth Retardation | - | - |
Xyntha | Phase 3 | Hemophilia A | - | - |
Zavegepant (BHV-3500) | Phase 3 | Acute Migraine | - | - |
Desvenlafaxine succinate sustained release 50 mg | Phase 3 | Major Depressive Disorder | - | - |
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
SU011248 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
Pantoprazole for approximately 9 weeks | Phase 3 | Gastroesophageal Reflux | - | - |
pantoprazole sodium enteric-coated spheroid | Phase 3 | Gastroesophageal Reflux | - | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | Respiratory Syncytial Virus | - | - |
Investigator's choice | Phase 3 | Lymphoma | - | - |
azithromycin (Zithromax) | Phase 3 | Pharyngitis | - | - |
IV Diclofenac | Phase 3 | Postoperative Pain | - | - |
Morphine | Phase 3 | Sedation | - | - |
oxaliplatin | Phase 3 | Colorectal Neoplasms | - | - |
Piperacillin/Tazobactam (Tazocin) | Phase 3 | Hematologic Neoplasms | - | - |
effervescent ibuprofen tablets | Phase 3 | Pain | - | - |
CP690,550 | Phase 3 | Ulcerative Colitis | - | - |
Fesoterodine PR 8 mg | Phase 3 | Urinary Bladder, Neurogenic | - | - |
mycophenolate mofetil | Phase 3 | Graft vs Host Disease | - | - |
azithromycin sustained release | Phase 3 | Pneumonia | - | - |
FOLFIRI regimen | Phase 3 | Colorectal Cancer | - | - |
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release) | Phase 3 | Osteoarthritis | - | - |
leucovorin | Phase 3 | Colorectal Carcinoma | - | - |
azithromycin SR (Zithromax; compound: CP-62,993) | Phase 3 | Maxillary Sinusitis | - | - |
clarithromycin extended release (ER) | Phase 3 | Pneumonia | - | - |
Xiapex | Phase 3 | Dupuytren's Contracture | - | - |
MTZ | Phase 3 | Complicated Intra-abdominal Infection | - | - |
anastrozole | Phase 3 | Breast Neoplasms | - | - |
Standard of Care | Phase 3 | Macular Edema Associated With Diabetes Mellitus | - | - |
vaccine-13vPnC | Phase 3 | Pneumococcal Infections | - | - |
PF-04965842 | Phase 3 | Atopic Dermatitis | - | - |
ATM-AVI | Phase 3 | Complicated Intra-Abdominal Infections, cIAIs | - | - |
Recombinant Coagulation Factor IX (BeneFIX) | Phase 3 | Hemophilia B | - | - |
Ibuprofen 250 mg / Acetaminophen 500 mg | Phase 3 | Fever | - | - |
Celecoxib | Phase 3 | Schizophrenia | - | - |
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl | Phase 3 | Encephalitis, Tick-Borne | - | - |
Xalacom | Phase 3 | Glaucoma, Open-Angle | - | - |
Tanezumab 5 mg SC | Phase 3 | Low Back Pain | - | - |
Amlodipine | Phase 3 | Hypertension | - | - |
Topical IBU twice daily | Phase 3 | Ankle Injuries | - | - |
PLD | Phase 3 | Ovarian Cancer | - | - |
Lorlatinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
PMI-150 (intranasal ketamine) | Phase 3 | Pain, Postoperative | - | - |
Ibuprofen 600 mg Immediate Release/Extended Release Caplet | Phase 3 | Analgesia | - | - |
Clostridium difficile | Phase 3 | Clostridium Difficile Associated Disease | - | - |
PD 0332334 | Phase 3 | Generalized Anxiety Disorder | - | - |
Taxotere® | Phase 3 | Early Breast Cancer | - | - |
Ramipril and hydrochlorothiazide | Phase 3 | Hypertension | - | - |
PD-0332991 | Phase 3 | Neoplasms | - | - |
UFT | Phase 3 | Colon Cancer | - | - |
PF-07275315 dose 1 | Phase 3 | Moderate to Severe Chronic Obstructive Pulmonary Disease | - | - |
PF-08653944 | Phase 3 | Obesity | - | - |
5-FU | Phase 3 | Neoplasms | - | - |
Leuprolide Open Label | Phase 3 | Hormone Sensitive Prostate Cancer | - | - |
MabThera® | Phase 3 | Follicular Lymphoma | - | - |
MenACWY-CRM | Phase 3 | Meningococcal Vaccine | - | - |
DA-9501 | Phase 3 | Sedation | - | - |
paclitaxel | Phase 3 | Breast Neoplasms | - | - |
rLP2086 | Phase 3 | Healthy | - | - |
Investigational Medical Product (IMP) administered in parent study | Phase 3 | Osteoarthritis | - | - |
VENLAFAXINE | Phase 3 | Panic Disorders | - | - |
tacrolimus | Phase 3 | Kidney Transplantation | - | - |
PF-05280586 | Phase 3 | Rheumatoid Arthritis | - | - |
PG4 | Phase 3 | Pneumococcal Disease | - | - |
Quadrivalent influenza modRNA vaccine | Phase 3 | Influenza, Human | - | - |
CE 0.45 mg/MPA 1.5mg | Phase 3 | Endometrial Hyperplasia | - | - |
voxelotor | Phase 3 | Sickle Cell Disease | - | - |
Standard Ibuprofen | Phase 3 | Pain | - | - |
23vPS | Phase 3 | Vaccines, Pneumococcal Conjugate Vaccine | - | - |
Solution Vehicle | Phase 3 | Onychomycosis of Toenails | - | - |
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg | Phase 3 | Contraception | - | - |
Megestrol acetate | Phase 3 | Metastatic Breast Cancer | - | - |
Lorazepam | Phase 3 | Reflex Epilepsy, Photosensitive | - | - |
RSVpreF MDV | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
TBE vaccine 0.5 mL | Phase 3 | Tick-Borne Encephalitis | - | - |
Exubera (inhaled insulin) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Plant cell expressed recombinant glucocerebrosidase (prGCD) | Phase 3 | Gaucher Disease | - | - |
ibuzatrelvir | Phase 3 | COVID-19 Infection | - | - |
Inotuzumab ozogamicin | Phase 3 | ACUTE LYMPHOBLASTIC LEUKEMIA | - | - |
7vPnC | Phase 3 | Vaccines, Pneumococcal | - | - |
Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) | Phase 3 | Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | - | - |
FLAG (fludarabine, cytarabine and G-CSF) | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
MenABCWY | Phase 3 | Meningococcal Vaccine | - | - |
PF-06462700 | Phase 3 | Aplastic Anemia | - | - |
Multivalent Group B streptococcus vaccine | Phase 3 | Group B Streptococcus Infections | - | - |
Infanrix hexa | Phase 3 | Healthy | - | - |
PF-06651600 Induction Dose | Phase 3 | Alopecia Areata | - | - |
C.difficile vaccine | Phase 3 | Clostridioides Difficile Associated Disease | - | - |
Celebrex | Phase 3 | Osteoarthritis,Knee | - | - |
Abemaciclib | Phase 3 | Breast Cancer | - | - |
propiverine | Phase 3 | Urinary Bladder, Overactive | - | - |
ATRA plus 6-MP and MTX | Phase 3 | Leukemia, Myelocytic, Acute | - | - |
Sirolimus (Rapamune®) | Phase 3 | Renal Transplant | - | - |
somatrogon | Phase 3 | Growth Hormone Deficiency | - | - |
ampicillin sodium/sulbactam sodium | Phase 3 | Pneumonia, Bacterial | - | - |
bifeprunox, olanzapine | Phase 3 | Schizophrenia | - | - |
(PN-152,243)/PN-196,444 | Phase 3 | Neoplasms | - | - |
pantoprazole sodium enteric-coated spheroid suspension | Phase 3 | Gastroesophageal Reflux | - | - |
Chemotherapy Regimen 1 | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
ALO-02 | Phase 3 | Chronic Pain | - | - |
exemestane (Aromasin) | Phase 3 | Breast Neoplasms | - | - |
somatropin - GH naïve pediatric cohort | Phase 3 | Prader-Willi Syndrome | - | - |
Sirolimus (RAPAMUNE) | Phase 3 | Graft vs Host Disease | - | - |
Meningococcal group C polysaccharide conjugate vaccine | Phase 3 | Neisseria Meningitidis | - | - |
Donepezil (Aricept) | Phase 3 | Alzheimer Disease | - | - |
Moxifloxacin | Phase 3 | Chronic Bronchitis | - | - |
binodenoson | Phase 3 | Coronary Artery Disease | - | - |
Itraconazole | Phase 3 | Antifungal Prophylaxis of Invasive Fungal Infections | - | - |
bivalent rLP2086 | Phase 3 | Meningococcal Infection | - | - |
Inhaled human insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Temozolomide | Phase 3 | Glioblastoma | - | - |
Hib | Phase 3 | Pneumococcal Infections | - | - |
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) | Phase 3 | Pneumococcal Disease | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
FDC IBU/APAP 250 mg/500 mg | Phase 3 | Pain | - | - |
Matching vehicle control | Phase 3 | Dermatitis, Atopic | - | - |
Ritlecitinib 50 mg | Phase 3 | Chronic Spontaneous Urticaria | - | - |
Avelumab | Phase 3 | Urothelial Cancer | - | - |
DVS-233 SR (desvenlafaxine sustained release ) | Phase 3 | Major Depressive Disorder | - | - |
Insulin Lispro | Phase 3 | Diabetes Mellitus | - | - |
Cyclosporine A | Phase 3 | Renal Transplantation | - | - |
13 valent pneumococcal conjugate vaccine with Polysorbate 80 | Phase 3 | Vaccines, Pneumococcal | - | - |
Meropenem | Phase 3 | Complicated Intra-abdominal Infections | - | - |
MET097 | Phase 3 | Obesity | - | - |
RSVpreF (Group 1) | Phase 3 | RSV | - | - |
Imipenem-cilastatin | Phase 3 | Skin Infection | - | - |
Diclofenac | Phase 3 | Spondylitis, Ankylosing | - | - |
Pediacel | Phase 3 | Vaccines, Pneumococcal | - | - |
Pemetrexed/Cisplatin | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | - | - |
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg | Phase 3 | Menopause | - | - |
Amoxicillin/clavulinic acid | Phase 3 | Bronchitis, Chronic | - | - |
desvenlafaxine succinate (DVS) SR | Phase 3 | Vasomotor Symptoms | - | - |
PF-06823859 | Phase 3 | Myositis | - | - |
Ritlecitinib | Phase 3 | Stable Nonsegmental Vitiligo | - | - |
Nonacog alfa | Phase 3 | Hemophilia B | - | - |
Novel Ibuprofen | Phase 3 | Pain | - | - |
AG-013736 | Phase 3 | Carcinoma, Pancreatic Ductal | - | - |
Epoetin Hospira Arm | Phase 3 | Chronic Kidney Disease (CKD) | - | - |
Azithromycin/Chloroquine | Phase 3 | Malaria, Falciparum | - | - |
Imipenem | Phase 3 | Bacterial Pneumonia | - | - |
marstacimab | Phase 3 | Hemophilia A | - | - |
Sunitinib | Phase 3 | Neuroendocrine Tumors | - | - |
Bosutinib | Phase 3 | Polycystic Kidney, Autosomal Dominant | - | - |
Inhaled Insulin | Phase 3 | Asthma | - | - |
Rimegepant | Phase 3 | Acute Migraine | - | - |
Bazedoxifene/Conjugate Estrogens (CE) | Phase 3 | Endometrial Hyperplasia | - | - |
7-valent Pneumococcal Conjugate Vaccine | Phase 3 | Pneumococcal Infection | - | - |
Modified Bolus 5-FU/LV with Irinotecan | Phase 3 | Colorectal Neoplasms | - | - |
varenicline (CP-526,555) | Phase 3 | Smoking Cessation | - | - |
Tigecycline | Phase 3 | Gram-Positive Bacterial Infections | - | - |
fesoterodine fumarate | Phase 3 | Overactive Bladder | - | - |
amoxicillin | Phase 3 | Tonsillitis | - | - |
SPM 907 | Phase 3 | Overactive Bladder Syndrome | - | - |
Somatropin | Phase 3 | Endocrine System Diseases | - | - |
Parecoxib Sodium/Valdecoxib | Phase 3 | Pain | - | - |
Palbociclib | Phase 3 | Breast Cancer | - | - |
Pregabalin | Phase 3 | Epilepsy, Partial | - | - |
amoxicillin/clavulanate postassium (Augmentin ES-600) | Phase 3 | Acute Otitis Media | - | - |
DVS-233 | Phase 3 | Menopause | - | - |
Tisotumab Vedotin | Phase 3 | Cervical Cancer | - | - |
13-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines | - | - |
Sorafenib | Phase 3 | Renal Cell Carcinoma | - | - |
levonorgestrel/ethinyl estradiol | Phase 3 | Menstruation Disturbances | - | - |
Ritlecitinib higher dose | Phase 3 | Severe Alopecia Areata | - | - |
PF-07321332 | Phase 3 | COVID-19 | - | - |
AN2690 Topical Solution, 5% | Phase 3 | Onychomycosis of Toenails | - | - |
AN2728 Topical Ointment, 2% | Phase 3 | Dermatitis, Atopic | - | - |
Pentavac | Phase 3 | Vaccines, Pneumococcal | - | - |
Encorafenib | Phase 3 | BRAF V600E-mutant Metastatic Colorectal Cancer | - | - |
20-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Disease | - | - |
Talazoparib with enzalutamide | Phase 3 | mCRPC | - | - |
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT) | Phase 3 | Meningitis, Meningococcal | - | - |
Letrozole | Phase 3 | Breast Neoplasms | - | - |
Genotropin | Phase 3 | Idiopathic Short Stature | - | - |
oxycodone HCl and naltrexone HCl extended-release capsules | Phase 3 | Chronic Noncancer Pain | - | - |
Zavegepant | Phase 3 | Migraine | - | - |
pantoprazole | Phase 3 | Gastroesophageal Reflux | - | - |
[S,S]-Reboxetine | Phase 3 | Fibromyalgia | - | - |
PF-06651600 | Phase 3 | Active Non-segmental Vitiligo | - | - |
Taliglucerase alfa | Phase 3 | Gaucher Disease | - | - |
fluconazole | Phase 3 | Tinea Capitis | - | - |
PF-06410293 | Phase 3 | Rheumatoid Arthritis | - | - |
linezolid | Phase 3 | Febrile Neutropenia | - | - |
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) | Phase 3 | Neisseria Meningitidis (Bacterial Meningitis) | - | - |
Desvenlafaxine succinate sustained-release (DVS SR) | Phase 3 | Depression | - | - |
Epirubicin with Cyclophosphamide, followed by a Taxane | Phase 3 | Adenocarcinoma | - | - |
Ceftazidime-avibactam | Phase 3 | Complicated Intra-abdominal Infection | - | - |
talazoparib plus enzalutamide | Phase 3 | Prostate Cancer | - | - |
Ibuprofen/Caffeine | Phase 3 | Pain | - | - |
PF-06947386 | Phase 3 | Complicated Intra-abdominal Infection | - | - |
tucatinib | Phase 3 | HER2-positive Breast Cancer | - | - |
CP-690,550 | Phase 3 | Crohn's Disease | - | - |
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) | Phase 3 | Encephalitis, Tick-borne | - | - |
Bococizumab (PF-04950615;RN316) | Phase 3 | Hyperlipidemia | - | - |
Azithromycin | Phase 3 | Community Acquired Pneumonia (CAP) | - | - |
ponsegromab | Phase 3 | Non-small Cell Lung Cancer | - | - |
Dexmedetomidine | Phase 3 | Sedation | - | - |
DVS-233 SR | Phase 3 | Major Depressive Disorder | - | - |
Dacomitinib (PF-00299804) | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Genotropin (PN-180,307) Somatropin | Phase 3 | Infant, Small for Gestational Age | - | - |
exemestane | Phase 3 | Breast Neoplasms | - | - |
Erlotinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
sumanirole | Phase 3 | Parkinson Disease | - | - |
UK-390,957 | Phase 3 | Ejaculation | - | - |
torcetrapib/atorvastatin | Phase 3 | Hyperlipidemia | - | - |
RSVpreF | Phase 3 | RSV Infection | - | - |
disitamab vedotin | Phase 3 | Urothelial Carcinoma | - | - |
Fesoterodine | Phase 3 | Overactive Bladder Syndrome | - | - |
Nimenrix | Phase 3 | Meningococcal Vaccine | - | - |
7-Valent Pneumococcal Conjugate Vaccine (7vPnC) | Phase 3 | Healthy Subjects | - | - |
Meningococcal vaccine GSK134612 | Phase 3 | Infections, Meningococcal | - | - |
13-valent pneumococcal conjugate vaccine (13vPnC) | Phase 3 | Healthy Subjects | - | - |
Moroctocog alfa (AF-CC) | Phase 3 | Hemophilia A | - | - |
lecozotan SR (SRA-333) | Phase 3 | Alzheimer Disease | - | - |
tanezumab 10 mg | Phase 3 | Osteoarthritis | - | - |
Desvenlafaxine Succinate Sustained-Release 10mg | Phase 3 | Major Depressive Disorder | - | - |
olmesartan alone or in combination with hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
7 valent pneumococcal conjugate vaccine | Phase 3 | Vaccines, Pneumococcal | - | - |
Inhaled human insulin (EXUBERA™) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Tolterodine ER | Phase 3 | Overactive Bladder | - | - |
Fragmin | Phase 3 | Diabetic Foot Ulcer | - | - |
Tafamidis | Phase 3 | Transthyretin (TTR) Amyloid Cardiomyopathy | - | - |
Interferon-alfa | Phase 3 | Carcinoma, Renal Cell | - | - |
tanezumab | Phase 3 | Arthritis | - | - |
13vPnC | Phase 3 | Vaccines, Pneumococcal Conjugate Vaccine | - | - |
Rifabutin | Phase 3 | Mycoses | - | - |
endocrine-modulating drug therapy | Phase 3 | Prostate Cancer | - | - |
Ibuprofen Sodium | Phase 3 | Pain | - | - |
ceftazidim-avibactam (CAZ-AVI, experimental product) | Phase 3 | Nosocomial Pneumonia (NP) | - | - |
Gefitinib | Phase 3 | Non-small Cell Lung Cancer With EGFR-Activating Mutations | - | - |
Carboplatin | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
leflunomide | Phase 3 | Prostate Cancer | - | - |
Cyclosporin or tacrolimus | Phase 3 | Graft Rejection | - | - |
Edotecarin | Phase 3 | Breast Neoplasms | - | - |
Ceftaroline fosamil | Phase 3 | Complicated Skin and Soft Tissue Infection | - | - |
Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg | Phase 3 | Oral Contraceptive | - | - |
Enbrel (etanercept) | Phase 3 | Ankylosing Spondylitis | - | - |
Zmax | Phase 3 | Otitis Media | - | - |
Venlafaxine ER | Phase 3 | Panic Disorder | - | - |
vancomycin with aztreonam | Phase 3 | Skin Diseases, Infectious | - | - |
ARV-471 | Phase 3 | Advanced Breast Cancer | - | - |
ARV-471 (PF-07850327) | Phase 3 | Breast Cancer | - | - |
valdecoxib | Phase 3 | Pain | - | - |
Havrix (HAV) | Phase 3 | Meningococcal Vaccine | - | - |
NWP09 | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
PF-07220060 | Phase 3 | Liposarcoma | - | - |
Rimegepant (PF-07899801) | Phase 3 | Acute Treatment of Migraine | - | - |
13 valent Pneumococcal Conjugate Vaccine | Phase 3 | Pneumococcal Infections | - | - |
7vPnc pneumococcal conjugate vaccine | Phase 3 | Vaccines, Pneumococcal | - | - |
Bifeprunox | Phase 3 | Schizophrenia | - | - |
Epoetin Hospira | Phase 3 | Chronic Renal Failure Requiring Hemodialysis | - | - |
Sunitinib malate | Phase 3 | Breast Neoplasms | - | - |
Ethambutol hydrochloride | Phase 3 | Mycobacterium Avium-intracellulare Infection | - | - |
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER) | Phase 3 | Pain | - | - |
ritonavir | Phase 3 | COVID-19 | - | - |
ReFacto AF | Phase 3 | Hemophilia A | - | - |
binimetinib | Phase 3 | MSS | - | - |
ropinirole | Phase 3 | Parkinson Disease | - | - |
Sirolimus | Phase 3 | Renal Transplantation | - | - |
Desvenlafaxine Succinate Sustained-Release | Phase 3 | Major Depressive Disorder | - | - |
Gemcitabine | Phase 3 | Pancreatic Neoplasms | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | - | - |
Ceftazidime - Avibactam ( CAZ-AVI) | Phase 3 | Complicated Urinary Tract Infection | - | - |
Vancomycin | Phase 3 | Bacterial Infections | - | - |
Dacarbazine | Phase 3 | Metastatic or Unresectable Cutaneous Melanoma | - | - |
Etanercept | Phase 3 | Pulmonary Fibrosis | - | - |
Avelumab (MSB0010718C) | Phase 3 | Renal Cell Cancer | - | - |
Steroids | Phase 3 | Kidney Failure | - | - |
rFIX | Phase 3 | Hemophilia B | - | - |
In open-label phase: treatment with tofacitinib | Phase 3 | Arthritis Juvenile Idiopathic | - | - |
Ibuprofen 600 mg ER | Phase 3 | Pain | - | - |
PF-08653945 | Phase 2 | Overweight | - | - |
Tanezumab 20 mg IV | Phase 2 | Low Back Pain | - | - |
PF-04360365 10 mg/kg | Phase 2 | Alzheimer's Disease | - | - |
Prednisone | Phase 2 | Prostatic Neoplasms | - | - |
PF-06826647 | Phase 2 | Psoriasis | - | - |
PF-07976016 | Phase 2 | Obesity | - | - |
852A | Phase 2 | Melanoma | - | - |
PD 0200390 | Phase 2 | Nonrestorative Sleep | - | - |
PF-03654764 | Phase 2 | Allergic Rhinitis | - | - |
60 mg/kg azithromycin ER | Phase 2 | Acute Otitis Media | - | - |
CP-751, 871 | Phase 2 | Colorectal Neoplasm | - | - |
PF-07850327, ARV-471, vepdegestrant | Phase 2 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer | - | - |
CP-690-550 | Phase 2 | Arthritis, Rheumatoid | - | - |
SU-011,248 | Phase 2 | Kidney Neoplasms | - | - |
PF-610,355 | Phase 2 | Asthma | - | - |
UK0369,003 | Phase 2 | Impotence | - | - |
Multivalent Pneumococcal Vaccine - Formulation 1 | Phase 2 | Pneumococcal Disease | - | - |
0.04 mg/kg CpG 7909 | Phase 2 | Carcinoma, Breast | - | - |
PF-04217329 - Lowest Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral | Phase 2 | Osteoarthritis of the Knee | - | - |
Combination [RSVpreF+BNTb162b2] | Phase 2 | Healthy Participants | - | - |
PD-0299685 | Phase 2 | Hot Flashes | - | - |
PF-04449913 | Phase 2 | Acute Myeloid Leukemia | - | - |
axitinib | Phase 2 | Carcinoma, Non-Small Cell Lung | - | - |
CP-690,550 Vehicle | Phase 2 | Dry Eye Syndromes | - | - |
PF-06291874 | Phase 2 | Diabetes Mellitus, Type II | - | - |
Mylotarg (gemtuzumab ozogamicin) Injection | Phase 2 | Acute Myelogenous Leukemia | - | - |
AN2690, 2.5% | Phase 2 | Distal, Subungual Onychomycosis | - | - |
tofacitinib ointment 20 mg/g | Phase 2 | Psoriasis Vulgaris | - | - |
AN2728 ointment, 2% | Phase 2 | Psoriasis | - | - |
PF-06882961 | Phase 2 | Diabetes | - | - |
PF-00489791 | Phase 2 | Diabetic Nephropathies | - | - |
PD 0299685 at 15mg BID | Phase 2 | Interstitial Cystitis | - | - |
UK-453, 061 | Phase 2 | HIV-1 | - | - |
PF-05089771 150 mg | Phase 2 | Diabetic Neuropathy, Painful | - | - |
Celecoxib, COX-2 inhibitor; oral | Phase 2 | Dental Pain | - | - |
ARRY-502, CRTh2 antagonist; oral | Phase 2 | Asthma | - | - |
Levonorgestrel | Phase 2 | Ovulation | - | - |
Formulation A | Phase 2 | Respiratory Tract Infections | - | - |
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection | Phase 2 | Shingles | - | - |
CPG 7909 Injection | Phase 2 | Carcinoma, Melanoma | - | - |
PF-04383119 | Phase 2 | Cystitis, Interstitial | - | - |
PF-06882961 (Cohorts 1 and 2) | Phase 2 | Obesity | - | - |
Multivalent | Phase 2 | Pneumococcal Infections | - | - |
Bazedoxifene | Phase 2 | Postmenopausal Osteoporosis | - | - |
Filibuvir | Phase 2 | Hepatitis | - | - |
PF-05221304 | Phase 2 | Nonalcoholic Fatty Liver Disease | - | - |
ARRY-520, KSP(Eg5) inhibitor; intravenous | Phase 2 | Multiple Myeloma | - | - |
AN2728 | Phase 2 | Psoriasis | - | - |
FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]) | Phase 2 | Colorectal Neoplasms | - | - |
vabicaserin | Phase 2 | Schizophrenia | - | - |
TMI-005 | Phase 2 | Rheumatoid Arthritis | - | - |
Crisaborole ointment 2% BID | Phase 2 | Dermatitis, Atopic | - | - |
ibuprofen | Phase 2 | Pain | - | - |
Doxycycline | Phase 2 | Non Small Cell Lung Cancer (NSCLC) | - | - |
ARRY-438162, MEK inhibitor; oral | Phase 2 | Rheumatoid Arthritis | - | - |
ACC-001 | Phase 2 | Alzheimer's Disease | - | - |
FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil) | Phase 2 | Unresectable or Metastatic Colorectal Cancer | - | - |
MET097 Injection | Phase 2 | Obesity in Diabetes | - | - |
IMA-638 | Phase 2 | Asthma | - | - |
SKI-606 (Bosutinib) | Phase 2 | Chronic Myelogenous Leukemia | - | - |
Influenza ModRNA Vaccine | Phase 2 | Influenza, Human | - | - |
SCA-136 (200 mg) | Phase 2 | Schizophrenia | - | - |
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6) | Phase 2 | Group B Streptococcal Infections | - | - |
Tofacitinib 2 mg | Phase 2 | Ankylosing Spondylitis | - | - |
meningococcal B rLP2086 vaccine. | Phase 2 | Meningitis, Meningococcal | - | - |
PF-06463922 | Phase 2 | ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC | - | - |
Tofacitinib ointment 20mg/g | Phase 2 | Dermatitis, Atopic | - | - |
PF-04217329 | Phase 2 | Glaucoma, Open-Angle | - | - |
Ezetimibe | Phase 2 | Hypercholesterolemia | - | - |
vepdegestrant | Phase 2 | Breast Cancer | - | - |
PF-04236921 | Phase 2 | Crohn's Disease | - | - |
Tamsulosin | Phase 2 | Prostatic Hyperplasia | - | - |
PF-06865571 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Chemotherapy Regimen 2 | Phase 2 | Carcinoma | - | - |
Vaccine Candidate #1 | Phase 2 | Healthy Adults | - | - |
IMA-638 is a biologic | Phase 2 | Asthma | - | - |
CPG 7909 | Phase 2 | Carcinoma, Non-Small Cell Lung | - | - |
Anrukinzumab | Phase 2 | Colitis, Ulcerative | - | - |
AG013736 | Phase 2 | Thyroid Neoplasms | - | - |
azithromycin immediate release (Zithromax) | Phase 2 | Pharmacokinetics | - | - |
PH-797804 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Tolterodine & Pregabalin | Phase 2 | Overactive Bladder | - | - |
Herceptin® | Phase 2 | Carcinoma, Metastatic Breast | - | - |
PF-00592379 | Phase 2 | Impotence | - | - |
Peg-Intron | Phase 2 | Hepatitis C | - | - |
PF-07868489 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
PF-06700841 | Phase 2 | Psoriatic Arthritis | - | - |
Filanesib, KSP (Eg5) inhibitor; intravenous | Phase 2 | Advanced Multiple Myeloma | - | - |
Enfortumab Vedotin | Phase 2 | Urothelial Cancer | - | - |
exemestane (Aromasin®) | Phase 2 | Breast Neoplasms | - | - |
SS-RBX | Phase 2 | Urinary Incontinence, Stress | - | - |
sulopenem and PF-03709270 | Phase 2 | Pneumonia, Bacterial | - | - |
bapineuzumab | Phase 2 | Alzheimer Disease | - | - |
RV521 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Allegra | Phase 2 | Allergic Rhinitis | - | - |
Irinotecan plus capecitabine | Phase 2 | Carcinoma, Hepatocellular | - | - |
Elranatamab (PF-06863135) | Phase 2 | Multiple Myeloma | - | - |
PF-00734200 30 mg QD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Anti-Beta Interferon (PF-06823859) | Phase 2 | Dermatomyositis | - | - |
Tasocitinib plus Methotrexate | Phase 2 | Rheumatoid Arthritis | - | - |
AG-013726 | Phase 2 | Colorectal Neoplasms | - | - |
PF-07220060 + PF-07104091 combination dose escalation | Phase 2 | Breast Cancer | - | - |
EXC 001 | Phase 2 | Scar Prevention | - | - |
SAM-531 | Phase 2 | Alzheimer Disease | - | - |
Celecoxib + Exemestane | Phase 2 | Breast Neoplasms | - | - |
WNT974 | Phase 2 | Metastatic Colorectal Cancer | - | - |
PF-04634817 | Phase 2 | Diabetic Nephropathy | - | - |
EXC 001 (currently called PF-06473871) | Phase 2 | Reduction in Severity of Skin Scarring | - | - |
CP-778,875 | Phase 2 | Dyslipidemia | - | - |
ACC-001 + QS-21 | Phase 2 | Alzheimer Disease | - | - |
CP-533, 536 | Phase 2 | Tibial Fractures | - | - |
SBI-087 | Phase 2 | Active Rheumatoid Arthritis | - | - |
ceftazidime/NXL104 + metronidazole | Phase 2 | Complicated Intra-abdominal Infections | - | - |
PF-04494700 - Low Dose Arm | Phase 2 | Alzheimer Disease | - | - |
cytarabine. | Phase 2 | Acute Myeloid Leukemia | - | - |
CCI-779 | Phase 2 | Multiple Sclerosis, Relapsing-Remitting | - | - |
rhBMP-2/CPM | Phase 2 | Fractures | - | - |
PELITREXOL/AG-2037 | Phase 2 | Colorectal Neoplasms | - | - |
CE-224,535 | Phase 2 | Arthritis, Rheumatoid | - | - |
BNT162b2 (Omi XBB.1.5)/RIV | Phase 2 | Influenza, Human | - | - |
sunitinib malate dose escalation | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
MultiStem low dose | Phase 2 | Colitis, Ulcerative | - | - |
rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy) | Phase 2 | Osteoporosis | - | - |
Carfilzomib, proteasome inhibitor; intravenous | Phase 2 | Advanced Multiple Myeloma | - | - |
PF-06835375 | Phase 2 | Primary Immune Thrombocytopenia | - | - |
Torisel | Phase 2 | Adenocarcinoma | - | - |
SPK-9001 | Phase 2 | Hemophilia B | - | - |
CP-866,087 | Phase 2 | Alcoholism | - | - |
PF-06835919 | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
ARRY-334543, EGFR/ErbB2 inhibitor; oral | Phase 2 | Advanced Cancer | - | - |
Tygacil | Phase 2 | Bacterial Infections | - | - |
ARRY-371797, p38 inhibitor; oral | Phase 2 | LMNA-Related Dilated Cardiomyopathy | - | - |
C. difficile vaccine (previously studied formulation). | Phase 2 | Clostridoides Difficile Associated Disease | - | - |
CP-751,871 | Phase 2 | Prostatic Neoplasms | - | - |
CPG10101 | Phase 2 | Hepatitis, Chronic Active | - | - |
PF-06372865 | Phase 2 | Chronic Low Back Pain | - | - |
lecozotan SR | Phase 2 | Alzheimer Disease | - | - |
RSV Vaccine | Phase 2 | Respiratory Tract Infection | - | - |
Kaletra | Phase 2 | HIV Infections | - | - |
BYL719 | Phase 2 | Colorectal Cancer | - | - |
MYO-029 | Phase 2 | Becker Muscular Dystrophy | - | - |
(Part C) MET097 | Phase 2 | Obesity and Overweight | - | - |
dalteparin | Phase 2 | Venous Thromboembolism | - | - |
HSP-130 | Phase 2 | Non-metastatic Breast Cancer | - | - |
SRA-333 | Phase 2 | Alzheimer's Disease | - | - |
Dacomitinib | Phase 2 | Non-small Cell Lung Cancer | - | - |
PF-00232798 | Phase 2 | HIV | - | - |
SB-525 (PF-07055480) | Phase 2 | Hemophilia A | - | - |
PF-07817883 | Phase 2 | SARS-CoV-2 Infection | - | - |
CI-1040 | Phase 2 | Colorectal Neoplasms | - | - |
PF-04171327 10 mg | Phase 2 | Rheumatoid Arthritis | - | - |
PF-07104091 monotherapy dose escalation | Phase 2 | Small Cell Lung Cancer | - | - |
PF-04950615 (RN316) | Phase 2 | Hypercholesterolemia | - | - |
NR2B NMDA Antagonist CP-101,606 (traxoprodil) | Phase 2 | Parkinson's Disease | - | - |
PF-04360365 0.1 mg/kg | Phase 2 | Alzheimer's Disease | - | - |
Sunitinib malate (SU011248) | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
PF-3512676 + Erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Low Dose PF-07328948 | Phase 2 | Heart Failure | - | - |
SU011248 (sunitinib) | Phase 2 | Carcinoma, Renal Cell Metastasis | - | - |
PF-04383119 (RN624) | Phase 2 | Low Back Pain | - | - |
PF-04937319 10 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Rapamune® (Sirolimus) | Phase 2 | Kidney Transplantation | - | - |
MET233 and MET097 | Phase 2 | Obesity and Obesity-related Medical Conditions | - | - |
NMDA Antagonist, CP-101,606 (traxoprodil) | Phase 2 | Depressive Disorder, Major | - | - |
SD-6010 | Phase 2 | Osteoarthritis | - | - |
CP-690,550 Ointment 1 | Phase 2 | Psoriasis | - | - |
AN2690 | Phase 2 | Onychomycosis | - | - |
Statin | Phase 2 | Hypercholesterolemia | - | - |
PF-00299804 | Phase 2 | Carcinoma, Non Small Cell Lung | - | - |
PF-08049820 | Phase 2 | Atopic Dermatitis | - | - |
Letrozole / Temsirolimus (CCI-779) | Phase 2 | Breast Neoplasms | - | - |
PF-04383119 (tanezumab) | Phase 2 | Osteoarthritis, Knee | - | - |
Vaccine | Phase 2 | Meningococcal Vaccine | - | - |
Sunitinib (SU011248) | Phase 2 | Liver Neoplasms | - | - |
Combination 1 | Phase 2 | Carcinoma, Renal Cell | - | - |
Samuraciclib | Phase 2 | Breast Cancer | - | - |
tacedinaline | Phase 2 | Pancreatic Cancer | - | - |
150 mg PF-04991532 | Phase 2 | Diabetes, Type 2 | - | - |
AN2728 Ointment Vehicle | Phase 2 | Psoriasis | - | - |
inotuzumab ozogamicin (CMC-544) | Phase 2 | Lymphoma, B-Cell | - | - |
Ceftazidime -avibactam | Phase 2 | Complicated Urinary Tract Infections | - | - |
CE-326,597 100 mg QD | Phase 2 | Weight Management | - | - |
CI-1033 | Phase 2 | Breast Neoplasms | - | - |
PF-06823859 low | Phase 2 | Dermatomyositis | - | - |
PF-04494700 (TTP488) | Phase 2 | Diabetic Nephropathy | - | - |
Repevax | Phase 2 | Meningococcal Vaccine | - | - |
PF-03654746 | Phase 2 | Excessive Daytime Sleepiness | - | - |
UK-453,061 | Phase 2 | HIV-1 | - | - |
PF-00217830 | Phase 2 | Schizophrenia | - | - |
EKB-569 | Phase 2 | Colorectal Neoplasms | - | - |
pregabalin/PF-00489791 | Phase 2 | Postherpetic Neuralgia | - | - |
CI 1033 | Phase 2 | Lung Neoplasms | - | - |
CP-690,550 + methotrexate | Phase 2 | Rheumatoid Arthritis | - | - |
PF-04136309 | Phase 2 | Osteoarthritis, Knee | - | - |
Open | Phase 2 | Chronic Kidney Disease | - | - |
QS-21 | Phase 2 | Alzheimer Disease | - | - |
ACC-001 3 μg/ QS-21 50 μg | Phase 2 | Alzheimer's Disease | - | - |
PF-00446687 | Phase 2 | Erectile Dysfunction | - | - |
Gefitinib + Sunitinib | Phase 2 | Carcinoma, Renal Cell | - | - |
ERB-041 | Phase 2 | Endometriosis | - | - |
PF-06838435 (formerly SPK-9001) | Phase 2 | Hemophilia B | - | - |
AG-013736 (Axitinib) | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Zithromax™ (azithromycin) 500mg tablets | Phase 2 | Sinusitis | - | - |
LEE011 | Phase 2 | Locally Advanced or Metastatic NRAS Mutant Melanoma | - | - |
Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor | Phase 2 | Kidney Neoplasms | - | - |
RN624 | Phase 2 | Neuralgia, Postherpetic | - | - |
PF-04937319 - 3mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
PF-04494700 | Phase 2 | Alzheimer's Disease | - | - |
PD-217,014 | Phase 2 | Irritable Bowel Syndrome | - | - |
AN2690, 5% | Phase 2 | Distal, Subungual Onychomycosis | - | - |
CP-690,550 Eye drops | Phase 2 | Dry Eye Syndromes | - | - |
Axitinib [AG-013736] | Phase 2 | Melanoma | - | - |
Tofimilast | Phase 2 | Asthma | - | - |
BGJ398 | Phase 2 | Melanoma | - | - |
PF-00734200 10 mg QD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Tick-borne Encephalitis Vaccine | Phase 2 | Tick-borne Encephalitis | - | - |
PF-02545920 | Phase 2 | Huntington's Disease | - | - |
Sumatriptan | Phase 2 | Migraine | - | - |
25 mg PF-04991532 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
PF-06650833 | Phase 2 | Acne Inversa | - | - |
Ibuprofen/acetaminophen | Phase 2 | Pain | - | - |
CP-526,555 (varenicline) | Phase 2 | Smoking Cessation | - | - |
PF-05089771 | Phase 2 | Postoperative Dental Pain | - | - |
MAC-321 | Phase 2 | Colorectal Neoplasms | - | - |
MET233 | Phase 2 | Obesity and Overweight | - | - |
PF-00610355 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
mPnC candidate | Phase 2 | Healthy Participants | - | - |
Dexmedetomidine, midazolam; fentanyl | Phase 2 | Intubated and Mechanically Ventilated Pediatric Subjects | - | - |
CP- 690 550 | Phase 2 | Ulcerative Colitis | - | - |
Capecitabine | Phase 2 | Breast Cancer | - | - |
PF-04191834 | Phase 2 | Asthma | - | - |
PF-04171327 | Phase 2 | Rheumatoid Arthritis | - | - |
mIRV | Phase 2 | Influenza, Human | - | - |
Risperidone | Phase 2 | Schizophrenia | - | - |
ILV-094 | Phase 2 | Rheumatoid Arthritis | - | - |
Leuprolide | Phase 2 | Prostate Cancer | - | - |
Anti-NGF AB | Phase 2 | Neoplasms | - | - |
Methotrexate plus ERB-041 for 12 weeks | Phase 2 | Rheumatoid Arthritis | - | - |
Vupanorsen | Phase 2 | Dyslipidemias | - | - |
active comparator | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Atomoxetine | Phase 2 | Attention Deficit Disorder With Hyperactivity | - | - |
cyclophosphamide | Phase 2 | Peripheral T-cell Lymphoma | - | - |
RN624 (PF-04383119) | Phase 2 | Osteoarthritis | - | - |
Elranatamab + Nirogacestat | Phase 2 | Multiple Myeloma | - | - |
AN2898 ointment, 1% | Phase 2 | Dermatitis, Atopic | - | - |
PBO | Phase 2 | Hypercholesterolemia | - | - |
AN2690 Solution, 5.0% | Phase 2 | Onychomycosis | - | - |
Tisotumab vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer | - | - |
Naproxen + PH-797804 | Phase 2 | Osteoarthritis | - | - |
ALO-01 | Phase 2 | Healthy | - | - |
Sitexsentin sodium | Phase 2 | Diastolic Heart Failure | - | - |
Capravirine | Phase 2 | Human Immunodeficiency Virus | - | - |
Bivalent rLP2086 Vaccine | Phase 2 | MENINGOCOCCAL INFECTION | - | - |
Meningococcal C | Phase 2 | Meningitis, Meningococcal | - | - |
PD 0348292 | Phase 2 | Venous Thrombosis | - | - |
PF-07275315 | Phase 2 | Asthma | - | - |
PF-06835919 Low Dose | Phase 2 | Non-alcoholic Fatty Liver Disease | - | - |
PF-00868554 | Phase 2 | Hepatitis C | - | - |
Staphylococcus aureus 4-antigen vaccine | Phase 2 | Staphylococcal Infections | - | - |
Sertraline and Elzasonan Combination | Phase 2 | Depressive Disorder, Major | - | - |
Part A: ATM-AVI Single Dose, Cohorts 1-4 | Phase 2 | Gram-negative Bacterial Infection | - | - |
MRE0094 | Phase 2 | Foot Ulcer, Diabetic | - | - |
BAT | Phase 2 | Gram-negative Bacterial Infections | - | - |
Investigational drug | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SU011248 capsule | Phase 2 | Carcinoma, Renal Cell | - | - |
PF-07220060 CDK4 inhibitor | Phase 2 | Advanced or Metastatic Breast Cancer | - | - |
Bortezomib | Phase 2 | Multiple Myeloma | - | - |
Pediatric HAV vaccine | Phase 2 | Meningococcal B Disease | - | - |
AN2728 Topical Ointment, 2% QD | Phase 2 | Dermatitis, Atopic | - | - |
PF-05221304 Monotherapy | Phase 2 | Non-Alcoholic Fatty Liver Disease (NAFLD) | - | - |
Crisaborole ointment 2% | Phase 2 | Atopic Dermatitis | - | - |
PF-07264660 | Phase 2 | Atopic Dermatitis | - | - |
PF-3512676 | Phase 2 | Lymphoma, T-Cell, Cutaneous | - | - |
UK-369,003 | Phase 2 | Prostatic Hyperplasia | - | - |
PF-06700841 15 mg | Phase 2 | Systemic Lupus Erythematosus | - | - |
Tanezumab 10 mg IV | Phase 2 | Neoplasm Metastasis | - | - |
Ponezumab | Phase 2 | Cerebral Amyloid Angiopathy | - | - |
PF-07038124 ointment | Phase 2 | Atopic Dermatitis | - | - |
CP-547,632 | Phase 2 | Ovarian Neoplasms | - | - |
Esreboxetine | Phase 2 | Fibromyalgia | - | - |
maplirpacept (PF-07901801) | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
PF-04236921 SC injection | Phase 2 | Crohn's Disease | - | - |
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) | Phase 2 | Depression | - | - |
15-valent pneumococcal conjugate vaccine (PCV15) | Phase 2 | Pneumococcal Disease | - | - |
PF-04447943 | Phase 2 | Alzheimer's Disease | - | - |
ACC-001(3µg) + QS21 | Phase 2 | Alzheimer Disease | - | - |
PD 0332991 | Phase 2 | Breast Cancer | - | - |
SU014813 | Phase 2 | Breast Neoplasms | - | - |
Tdap | Phase 2 | Pneumococcal Infections | - | - |
rLP2086 + MCV4 + Tdap | Phase 2 | Vaccines | - | - |
(CP-6890,550) Tofacitinib | Phase 2 | Plaque Psoriasis | - | - |
PF-06473871 | Phase 2 | Reduction of Hypertrophic Skin Scarring | - | - |
meningococcal B rLP2086 vaccine candidate | Phase 2 | Meningitis, Meningococcal | - | - |
ARRY-371797, p38 inhibitor, oral | Phase 2 | LMNA-Related Dilated Cardiomyopathy | - | - |
PF-04457845 | Phase 2 | Osteoarthritis, Knee | - | - |
Recombinant Human Interleukin-11 (rhIL-11) | Phase 2 | Crohn Disease | - | - |
sitaxsentan (Thelin) | Phase 2 | Cardiac Surgery Subjects | - | - |
Bicalutamide | Phase 2 | Prostate Cancer | - | - |
Sunitinib Malate Continuous Daily Dosing | Phase 2 | Carcinoma, Renal Cell | - | - |
Combination Agent 1 | Phase 2 | Advanced/Metastatic Non-Small Cell Lung Cancer | - | - |
PF-07038124 ointment 0.01% | Phase 2 | Atopic Dermatitis | - | - |
NXL104/ceftazidime | Phase 2 | Complicated Urinary Tract Infection | - | - |
rLP2086 and Gardasil | Phase 2 | Vaccines | - | - |
Renal Transplantation
1 drug in this indication
Major Depressive Disorder
1 drug in this indication
Diabetes Mellitus
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PFIZER's drug pipeline?→
CatalystAlert tracks 761 drug candidates in PFIZER's (PFE) pipeline across Phase 3, Phase 2. Its lead program is FSME-IMMUN NEW 0.25 ml (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PFIZER's next FDA catalyst?→
PFIZER's (PFE) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PFE biotech catalysts?→
Add PFE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PFIZER's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
